Abstract
Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users. No effect of aspirin was seen in patients with wild-type PIK3CA. Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Aspirin / therapeutic use*
-
Biomarkers, Tumor / genetics*
-
Class I Phosphatidylinositol 3-Kinases
-
Colorectal Neoplasms / diagnosis*
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / mortality
-
Humans
-
Mutation / genetics*
-
Phosphatidylinositol 3-Kinases / genetics*
-
Prognosis
-
Survival Rate
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Biomarkers, Tumor
-
Phosphatidylinositol 3-Kinases
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CA protein, human
-
Aspirin